My ePortfolio Register   

Resistance to CDK4/6 inhibitors

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 12.05.17
Views: 1773

Dr Nicholas Turner - The Institute of Cancer Research, London, UK

Dr Turner speaks with ecancer at IMPAKT 2017 about the clinical utility and resistance pathways associated with CDK4/6 inhibitor therapy.

He highlights the significance of survival, response and tolerability among patients who respond to CDK 4/6 therapy, and outlines how further understanding of where and when these therapies fail can offer new treatment opportunities for patients.

CDK4/6 resistance was also discussed at IMPAKT 2017 by Dr Uzma Asghar.

Supported by a grant from Pfizer Inc.

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence